These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38124266)

  • 1. Cautionary note on regional consistency evaluation in multiregional clinical trials with binary outcomes.
    Homma G
    Pharm Stat; 2024; 23(3):385-398. PubMed ID: 38124266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance.
    Quan H; Zhao PL; Zhang J; Roessner M; Aizawa K
    Pharm Stat; 2010; 9(2):100-12. PubMed ID: 19499510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials.
    Liu JT; Tsou HH; Gordon Lan KK; Chen CT; Lai YH; Chang WJ; Tzeng CS; Hsiao CF
    Stat Med; 2016 Jun; 35(14):2301-14. PubMed ID: 26833851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing consistency across all regions in a multi-regional clinical trial.
    Tsou HH; James Hung HM; Chen YM; Huang WS; Chang WJ; Hsiao CF
    Pharm Stat; 2012; 11(4):295-9. PubMed ID: 22504851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional consistency and sample size considerations in a multiregional equivalence trial.
    Wu SC; Xu JF; Zhang XJ; Li ZW; He J
    Pharm Stat; 2020 Nov; 19(6):897-908. PubMed ID: 32716135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size allocation in multiregional equivalence studies.
    Liao JJZ; Yu Z; Li Y
    Pharm Stat; 2018 Sep; 17(5):570-577. PubMed ID: 29911346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of regional treatment effect in a multiregional clinical trial.
    Tsong Y; Chang WJ; Dong X; Tsou HH
    J Biopharm Stat; 2012 Sep; 22(5):1019-36. PubMed ID: 22946947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes.
    Chiang C; Hsiao CF
    Stat Methods Med Res; 2019 Jul; 28(7):2179-2195. PubMed ID: 29355082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative consistency of treatment effects in multiregional clinical trials.
    Tanaka Y; Li G; Wang Y; Chen J
    J Biopharm Stat; 2012 Sep; 22(5):988-1000. PubMed ID: 22946945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision rules and associated sample size planning for regional approval utilizing multiregional clinical trials.
    Chen X; Lu N; Nair R; Xu Y; Kang C; Huang Q; Li N; Chen H
    J Biopharm Stat; 2012 Sep; 22(5):1001-18. PubMed ID: 22946946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unified additional requirement in consideration of regional approval for multiregional clinical trials.
    Teng Z; Chen YF; Chang M
    J Biopharm Stat; 2017; 27(6):903-917. PubMed ID: 28287339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian multiregional clinical trials using model averaging.
    Bean NW; Ibrahim JG; Psioda MA
    Biostatistics; 2023 Apr; 24(2):262-276. PubMed ID: 34296263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional consistency assessment in multiregional clinical trials.
    Li G; Quan H; Wang Y
    J Biopharm Stat; 2024 Apr; ():1-13. PubMed ID: 38557292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size allocation to regions in a multiregional trial.
    Uesaka H
    J Biopharm Stat; 2009 Jul; 19(4):580-94. PubMed ID: 20183427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
    Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
    [No Abstract]   [Full Text] [Related]  

  • 18. Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.
    Diao G; Zeng D; Ibrahim JG; Rong A; Lee O; Zhang K; Chen Q
    J Biopharm Stat; 2017; 27(6):933-944. PubMed ID: 28296570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination for a specific region in a multiregional trial.
    Ko FS; Tsou HH; Liu JP; Hsiao CF
    J Biopharm Stat; 2010 Jul; 20(4):870-85. PubMed ID: 20496211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Quantitative Method for Weight Selection in SGDDP.
    Huang Q; Chen G; Yuan Z; Zhang Y; Wenrich J
    J Biopharm Stat; 2015; 25(6):1179-89. PubMed ID: 25365548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.